CX 516

Drug Profile

CX 516

Alternative Names: 1-BCP; Ampakine CX 516; AMPAlex; BDP-12; SPD 420

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cortex Pharmaceuticals
  • Class Piperidines
  • Mechanism of Action AMPA receptor agonists; AMPA receptor antagonists; Glutamate agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Alzheimer's disease; Attention-deficit hyperactivity disorder; Autistic disorder; Mild cognitive impairment; Schizophrenia; Sleep disorders; Stroke

Most Recent Events

  • 11 Oct 2004 Two studies have been added to the adverse events and Psychotic disorders therapeutic trials sections ,
  • 01 Jul 2004 Phase-II clinical trials in Sleep disorders in USA (unspecified route)
  • 20 Feb 2004 Data from a media release have been added to the Alzheimer's disease and Cognitive disorders therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top